Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최남경 | - |
dc.date.accessioned | 2024-05-24T16:30:04Z | - |
dc.date.available | 2024-05-24T16:30:04Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 2092-7193 | - |
dc.identifier.other | OAK-34822 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268522 | - |
dc.description.abstract | OBJECTIVES: To assess the risk of lymphadenopathy following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.METHODS: A self-controlled case series design was used to determine whether the risk of lymphadenopathy was higher in the 1-day to 42-day risk interval after coronavirus disease 2019 (COVID-19) vaccination compared to the control period. In addition, subgroup analyses were conducted according to baseline characteristics, time since vaccination, and sensitivity analyses adjusted for the length of the risk interval.RESULTS: The risk of developing lymphadenopathy in the risk interval (1-42 days) after COVID-19 vaccination compared to the control period was significantly increased, with a relative incidence (RI) of 1.17 (95% confidence interval [CI], 1.17 to 1.18) when the first, second, and third doses were combined. The RI was greater on the day of vaccination (1.47; 95% CI, 1.44 to 1.50). In subgroup analyses by baseline characteristics, a significantly increased risk or trend toward increased risk was observed in most subgroups except for those aged 70 years and older, with a significant increase in risk in younger individuals, those with a Charlson's comorbidity index < 5, and those who received mRNA vaccines (mRNA-1273 > BNT162b2). Within the 1-day to 42-day post-dose risk period, the relative risk was highest during the 1-day to 7-day post-dose period (1.59; 95% CI, 1.57 to 1.60) compared to the control period, and then the risk declined. In the sensitivity analysis, we found that the longer the risk window, the smaller the RI.CONCLUSIONS: SARS-CoV-2 vaccination is associated with a statistically significant increase in the risk of lymphadenopathy, and this risk was observed only with mRNA vaccines. | - |
dc.language | English | - |
dc.publisher | KOREAN SOC EPIDEMIOLOGY | - |
dc.subject | COVID-19 vaccines | - |
dc.subject | Lymphadenopathy | - |
dc.subject | Self-controlled case series | - |
dc.subject | Vaccine safety | - |
dc.title | Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis | - |
dc.type | Article | - |
dc.relation.volume | 45 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.journaltitle | EPIDEMIOLOGY AND HEALTH | - |
dc.identifier.doi | 10.4178/epih.e2023090|http://dx.doi.org/10.4178/epih.e2023090 | - |
dc.identifier.wosid | WOS:001148517000001 | - |
dc.author.google | Kim, Mi-Sook | - |
dc.author.google | Kim, Bongyoung | - |
dc.author.google | Choi, Jeong Pil | - |
dc.author.google | Choi, Nam-Kyong | - |
dc.author.google | Heo, Jung Yeon | - |
dc.author.google | Choi, Jun Yong | - |
dc.author.google | Lee, Joongyub | - |
dc.author.google | Kim, Sang Il | - |
dc.contributor.scopusid | 최남경(35486895900) | - |
dc.date.modifydate | 20240524113044 | - |